Mayo Clinic launches new gene panel cancer test to help tailor chemotherapy

NewsGuard 100/100 Score

Mayo Clinic announces the launch of CANCP, a new gene panel cancer test to help tailor chemotherapy to the individual patient based on the unique genomic signature of the patient's tumor. CANCP, an abbreviation for Solid Tumor Targeted Cancer Gene Panel by Next-Generation Sequencing, scans specific regions in 50 genes known to affect tumor growth and response to chemotherapy. The test is now available to Mayo Clinic patients and to providers worldwide through Mayo Medical Laboratories.

"Every patient's cancer is different, and oncology is moving away from treating cancer based on its location in the body in favor of selecting the best medication for the individual patient based on molecular changes in the tumor," says Axel Grothey, M.D., a Mayo Clinic oncologist who orders CANCP on selected tumors. "This test helps providers identify such molecular changes without infusing irrelevant details from genes that we know will not affect our choice of medications."

The test is a hotspot panel, which means it scans specific regions of individual genes — rather than the entire gene — in search of tumor mutations that influence response to chemotherapy. It is designed for testing of solid tumors and focuses on clinically actionable alterations.

"We worked closely with oncologists, pathologists and molecular geneticists to develop and implement a next-generation sequencing assay that will have actionable results for providers," says Benjamin Kipp, Ph.D., a Mayo Clinic molecular geneticist and CANCP's lead designer. "This test focuses on results that oncologists can use to help find the right drug the first time."

Testing is conducted in the CLIA-certified Next-Generation Sequencing Lab of the Mayo Clinic Department of Laboratory Medicine and Pathology (DLMP). This is the second next-generation sequencing panel test offered by DLMP and Mayo Medical Laboratories. The other is a 17-gene screening test for hereditary colorectal cancers. Both were developed in collaboration with the Mayo Clinic Center for Individualized Medicine.

Source: Mayo Clinic

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Aspirin's immune-boosting effects in colorectal cancer revealed